Free Trial
NASDAQ:HBIO

Harvard Bioscience (HBIO) Stock Price, News & Analysis

Harvard Bioscience logo
$0.58 -0.02 (-2.82%)
As of 02:41 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About Harvard Bioscience Stock (NASDAQ:HBIO)

Key Stats

Today's Range
$0.56
$0.60
50-Day Range
$0.60
$2.02
52-Week Range
$0.59
$4.70
Volume
275,566 shs
Average Volume
173,703 shs
Market Capitalization
$25.65 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$4.50
Consensus Rating
Buy

Company Overview

Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services for life science applications in the United States and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equipment for molecular level testing and research; and precision scientific measuring instrumentation and equipment, including data acquisition systems for cellular analysis, complete micro electrode array solutions for in vivo recordings, and in vitro systems for extracellular recordings. It also provides preclinical products that includes platform to assess physiological data from organisms for research, drug discovery, and drug development services comprising implantable and externally worn telemetry systems for use in research to collect cardiovascular, central nervous system, respiratory, and metabolic data; behavioral products; isolated organ and surgical products, instruments and accessories for tissue, and organ-based lab research, including surgical products, infusion systems, and behavior research systems; turn-key respiratory system solutions, including plethysmograph chambers, data acquisition hardware, physiological signal analysis software, and final report generation; inhalation and exposure systems; and GLP-capable data acquisition and analysis systems. The company markets its products through sales organizations, websites, and distributors to research scientists in pharmaceutical and biotechnology companies, universities, hospitals, and government laboratories; and contract research organizations and academic labs. It primarily sells its products under Harvard Apparatus, DSI, Buxco, Biochrom, BTX, Heka, Hugo Sachs, Multichannel Systems MCS GmbH, and Panlab brands. Harvard Bioscience, Inc. was founded in 1901 and is based in Holliston, Massachusetts.

Remove Ads

Harvard Bioscience Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
78th Percentile Overall Score

HBIO MarketRank™: 

Harvard Bioscience scored higher than 78% of companies evaluated by MarketBeat, and ranked 561st out of 655 stocks in the computer and technology sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Harvard Bioscience has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Harvard Bioscience has only been the subject of 1 research reports in the past 90 days.

  • Read more about Harvard Bioscience's stock forecast and price target.
  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Harvard Bioscience is -1.74, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Harvard Bioscience is -1.74, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Harvard Bioscience has a P/B Ratio of 0.34. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Harvard Bioscience's valuation and earnings.
  • Percentage of Shares Shorted

    2.56% of the float of Harvard Bioscience has been sold short.
  • Short Interest Ratio / Days to Cover

    Harvard Bioscience has a short interest ratio ("days to cover") of 3.9, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Harvard Bioscience has recently increased by 6.38%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Harvard Bioscience does not currently pay a dividend.

  • Dividend Growth

    Harvard Bioscience does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    2.56% of the float of Harvard Bioscience has been sold short.
  • Short Interest Ratio / Days to Cover

    Harvard Bioscience has a short interest ratio ("days to cover") of 3.9, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Harvard Bioscience has recently increased by 6.38%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Harvard Bioscience has a news sentiment score of -1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.74 average news sentiment score of Computer and Technology companies.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for Harvard Bioscience this week, compared to 5 articles on an average week.
  • Search Interest

    Only 3 people have searched for HBIO on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • MarketBeat Follows

    Only 1 people have added Harvard Bioscience to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Harvard Bioscience insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 9.00% of the stock of Harvard Bioscience is held by insiders.

  • Percentage Held by Institutions

    80.87% of the stock of Harvard Bioscience is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Harvard Bioscience's insider trading history.
Receive HBIO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Harvard Bioscience and its competitors with MarketBeat's FREE daily newsletter.

HBIO Stock News Headlines

A brutally honest economic warning for 2025 (see proof)
New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked side-by-side with figures like Warren Buffett, Alan Greenspan, Ron Paul, Jim Rickards, and Steve Forbes, to name but a few) says....
See More Headlines

HBIO Stock Analysis - Frequently Asked Questions

Harvard Bioscience's stock was trading at $2.11 at the beginning of the year. Since then, HBIO stock has decreased by 72.8% and is now trading at $0.5740.
View the best growth stocks for 2025 here
.

Harvard Bioscience, Inc. (NASDAQ:HBIO) announced its earnings results on Tuesday, November, 2nd. The medical instruments supplier reported $0.06 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.06. The medical instruments supplier earned $29.66 million during the quarter, compared to analysts' expectations of $28.10 million. Harvard Bioscience had a negative net margin of 14.57% and a negative trailing twelve-month return on equity of 4.64%.

Harvard Bioscience subsidiaries include Data Sciences International.

Top institutional investors of Harvard Bioscience include AMH Equity Ltd (5.73%), Royce & Associates LP (4.51%), Dimensional Fund Advisors LP (3.82%) and Granahan Investment Management LLC (3.71%).
View institutional ownership trends
.

Shares of HBIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Harvard Bioscience investors own include YETI (YETI), Advanced Micro Devices (AMD), Meta Platforms (META), NVIDIA (NVDA), Alphabet (GOOG), STAG Industrial (STAG) and Tesla (TSLA).

Company Calendar

Last Earnings
11/02/2021
Today
3/25/2025
Next Earnings (Estimated)
5/05/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Analytical instruments
Sub-Industry
Life Sciences Tools & Services
Current Symbol
NASDAQ:HBIO
Employees
490
Year Founded
1901

Price Target and Rating

Average Stock Price Target
$4.50
High Stock Price Target
$4.50
Low Stock Price Target
$4.50
Potential Upside/Downside
+651.4%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-3,410,000.00
Pretax Margin
-13.67%

Debt

Sales & Book Value

Annual Sales
$94.14 million
Cash Flow
$0.12 per share
Price / Cash Flow
5.16
Book Value
$1.71 per share
Price / Book
0.35

Miscellaneous

Free Float
39,691,000
Market Cap
$26.40 million
Optionable
Optionable
Beta
1.46

Social Links

A Beginner's Guide to Investing in Cannabis Cover

Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.

Get This Free Report

This page (NASDAQ:HBIO) was last updated on 3/25/2025 by MarketBeat.com Staff
From Our Partners